A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

Solid Tumors, KRAS Mutation Clinical Trial

Official title:

A Phase Ia/Ib, Open-label, Multicentre Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of BI 1823911 as a Monotherapy and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumours Expressing KRAS G12C Mutation

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04973163
• Other study ID #: 1472-0001
• Secondary ID: 2021-000460-29
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: August 3, 2021
• Est. completion date: December 27, 2024

Study information

• Verified date: April 2024
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is open to adults with different types of advanced or metastatic cancer (including lung cancer, colorectal cancer, pancreatic cancer, and bile duct cancer). This study is for people for whom previous treatment was not successful or no treatment exists.

People who have a tumour with a KRAS mutation can participate in the study. A KRAS mutation makes tumours grow faster. BI 1823911 and BI 1701963 are medicines that may turn off KRAS, each in a different way. In this study, BI 1823911 is given to people for the first time.

The purpose of this study is to find the highest dose of BI 1823911 that people can tolerate when taken alone and together with BI 1701963. The most suitable dose is used to find out whether BI 1823911 alone and in combination with BI 1701963 can make tumours shrink.

Participants can stay in the study as long as they benefit from treatment and can tolerate it.

During this time, participants take tablets of BI 1823911 alone or in combination with BI 1701963 once a day. The doctors regularly monitor the size of the tumour. Doctors also regularly record any unwanted effects and check participant's health.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30
• Est. completion date: December 27, 2024
• Est. primary completion date: November 29, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pathologically confirmed diagnosis of locally advanced or metastatic solid tumours, e.g. adenocarcinoma of the lung, colorectal cancer, pancreatic cancer or cholangiocarcinoma. Non-small cell lung cancer (NSCLC) patients with mixed histology are eligible if adenocarcinoma is the predominant histology.

• Documented disease progression despite appropriate prior standard therapies or for whom no standard therapy exists for their tumour type and disease stage.

• KRAS mutation status: Kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation in tumour tissue or blood based on previously performed local testing using a validated test.

• Provision of archival tumour tissue, if available, to confirm retrospectively KRAS G12C mutation status and for biomarker assessment.

• At least one target lesion that can be measured per Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 (radiated lesions do not qualify as target lesions). In patients who only have one target lesion, and a biopsy of the lesion is required, the baseline imaging must be performed before the biopsy or at the earliest two weeks after the biopsy.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Adequate organ function as follows:

• Absolute neutrophil count (ANC) =1.5 x 10^9/L (equivalent values: = 1.5 x 10³/µL or = 1500/mm³); hemoglobin =9.0 g/dL (equivalent values: = 90 g/L or = 5.6 mmol/L); platelets =100 x 10^9/L (equivalent values: = 100 x 10³/µL or = 100 x 10³/mm³) without the use of haematopoietic growth factors.

• Total bilirubin =1.5 times the upper limit of normal (ULN), or =4 x ULN for patients who are known to have Gilbert's syndrome.

• Creatinine =1.5 x ULN. If creatinine is >1.5 x ULN, patient is eligible if concurrent creatinine clearance =50 mL/min (equivalent value: 0.84mL/s) (measured or calculated by Cockcroft-Gault formula).

• Aspartate transaminase (AST) and alanine transaminase (ALT) =3 x ULN, for patients with liver metastases =5 x ULN.

• Age =18 years of age, or over the legal age of consent as required by local legislation.

Further inclusion criteria apply.

Exclusion Criteria:

• Previous anticancer chemotherapy within 3 weeks of the first administration of trial drug. Previous anticancer hormonal treatment or anticancer immunotherapy within 2 weeks of the first administration of trial drug.

• Previous treatment with Rat Sarcoma (RAS), Mitogen-activated protein kinase (MAPK) or Son of sevenless 1 (SOS1) targeting agents (only for monotherapy Parts A, B, and C).

• Radiotherapy within 2 weeks prior to start of treatment, provided recovery from related toxicity.

• Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to start of treatment or planned during the projected course of the trial, e.g. hip replacement.

• Previous treatment with any investigational agent(s) or targeted treatment within 28 days prior to start of treatment or 5 half-lives, whichever is shorter.

• Known history of hypersensitivity to any of the excipients of BI 1823911 tablets, or any contraindication to Midazolam (for Monotherapy Part B only).

• History or presence of cardiovascular abnormalities such as congestive heart failure New York Heart Association (NYHA) classification of =3, unstable angina or poorly controlled arrhythmia which are considered clinically relevant by the Investigator. Myocardial infarction within 6 months prior to start of treatment. Uncontrolled hypertension defined as: Blood pressure (BP) measured in a rested and relaxed condition, where systolic BP >=140 mmHg, or diastolic BP >= 90 mmHg, with or without medication.

• Left ventricular ejection fraction (LVEF) <50%. Further exclusion criteria apply.

Related Conditions & MeSH terms

• Solid Tumors, KRAS Mutation

Intervention

Drug:
• BI 1823911
BI 1823911
• BI 1701963
BI 1701963
• Midazolam
Midazolam - only administered in Part B (dose confirmation) of the Monotherapy Arm

Locations

Country	Name	City	State
Belgium	Brussels - HOSP Jules Bordet	Anderlecht/Brussels-Capital
Belgium	Edegem - UNIV UZ Antwerpen	Edegem/Antwerpen
Belgium	UNIV UZ Gent	Gent/Oost-Vlaanderen
Belgium	UZ Leuven	Leuven/Vlaams-Brabant
Spain	Hospital Vall d'Hebron	Barcelona
United Kingdom	The Christie Hospital	Manchester
United States	Mary Crowley Cancer Research Center	Dallas	Texas
United States	The University of Texas MD Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

United States,  Belgium,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose escalation (Part A) - Monotherapy and combination therapy: Number of patients experiencing Dose limiting toxicities (DLTs) during the Maximum tolerated dose (MTD) evaluation period for BI 1823911 in monotherapy and in each combination	DLTs are graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.	up to 28 days
Primary	Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Objective response (OR) defined as best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR)	BOR is determined according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.; BOR will consider all tumour assessments from first treatment administration until the earliest of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent.	up to 39 months
Secondary	Dose escalation (Part A) - Monotherapy and combination therapy: Number of patients experiencing DLTs during all treatment cycles for BI 1823911 in monotherapy and in each combination		up to 39 months
Secondary	Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Objective response (OR)	OR is defined as best overall response (BOR) of complete response (CR) or partial response (PR), both regardless of confirmation.; BOR is determined according to RECIST version 1.1. BOR will consider all tumour assessments from first treatment administration until the earliest of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent.	up to 39 months
Secondary	Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Duration of OR	Duration of OR is defined as the time from first documented CR or PR until disease progression or death (whichever occurs first) among patients with OR.	up to 39 months
Secondary	Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Tumour shrinkage (in millimetres)	Tumour shrinkage is defined as the difference between the minimum post-baseline sum of diameters of target lesions (longest for non-nodal lesions, short axis for nodal lesions) and the baseline sum of longest diameters of the same set of target lesions.	up to 39 months
Secondary	Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Progression-free survival (PFS) rate	PFS is defined as the time from first treatment administration until tumour progression according to RECIST version 1.1 or death from any cause, whichever occurs earlier.	at month 6
Secondary	All study parts: Number of patients with adverse events during the on-treatment period		up to 39 months
Secondary	All study parts, BI 1823911: Maximum concentration (Cmax)		up to 24 hours
Secondary	All study parts, BI 1823911: Steady state concentration (Css)		up to 24 hours
Secondary	All study parts, BI 1823911: Area under the plasma concentration-time curve from time zero to time t (AUCt)		up to 24 hours
Secondary	All study parts, BI 1823911: Area under the plasma concentration-time curve at steady state (AUCss)		up to 24 hours
Secondary	All study parts, BI 1701963: Maximum concentration (Cmax)		up to 24 hours
Secondary	All study parts, BI 1701963: Steady state concentration (Css)		up to 24 hours
Secondary	All study parts, BI 1701963: Area under the plasma concentration-time curve from time zero to time t (AUCt)		up to 24 hours
Secondary	All study parts, BI 1701963: Area under the plasma concentration-time curve at steady state (AUCss)		up to 24 hours

External Links

•   Related Info